

January 28, 2026

To,  
The Listing Department,  
**BSE LIMITED,**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort  
Mumbai- 400 001

To,  
The Listing Department  
**National Stock Exchange of India Limited,**  
Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C-1,  
G-Block, Bandra Kurla Complex,  
Mumbai -400051

Scrip Code : 543349

NSE Symbol : ACUTAAS

**Subject: Investor Presentation pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Dear Sir/Madam,

In accordance with Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Investor Presentation on third quarter and nine months ended financial results as on December 31, 2025 and other business matters.

This Investor Presentation will also be available on the website of the Company  
[www.acutaas.com](http://www.acutaas.com).


Kindly take the same on record.

Yours faithfully,  
**For, ACUTAAS CHEMICALS LIMITED**

**Ekta Kumari Srivastava**  
Company Secretary & Compliance Officer



Encl: Presentation



# EARNINGS PRESENTATION

---

**JANUARY 2026**



## Mr. Naresh Patel

Executive Chairman and Managing Director

"We continue to reinforce our core pharmaceutical intermediates business through the addition of CMO/CDMO opportunities alongside strengthening our business foundation by scaling battery chemicals and semiconductor chemicals verticals. These businesses, which are currently under active capital investment, are progressing steadily toward scale. Over the next three years, we expect each vertical to operate as an independent, self-sustaining growth engine, contributing meaningfully to our overall topline.

I am pleased to share that we have sustained strong growth momentum in Q3, driven by the continued ramp-up of our CDMO business. As we progress toward the end of the financial year, supported by a healthy order book and improved visibility, we are revising our revenue growth guidance upward—from 25% to approximately 30%."

(Mn.)

### Revenue for Q3 FY26

₹3,932

YoY 43.0%

### EBITDA for Q3 FY26

₹1,507

YoY 119.4%


### PAT for Q3 FY26

₹1,062

YoY 133.7%

# Q3 FY26 Financial Performance – Key Metrics

## Revenue from Operations





## EBITDA & EBITDA Margin

(₹ Mn.)

## PAT

(₹ Mn.)



## Q3 FY26 Earnings & Business Highlights

Robust growth in Advanced Pharmaceutical Intermediates business supported by strong Ramp up in CDMO, with specialty chemicals business growing steadily

Cost improvement measures and favorable product mix resulted in higher gross margins. This coupled with operating leverage contributed to strong EBITDA for the quarter

Robust EBITDA margins, led to a highest ever PAT for the quarter

# Q3 FY26 Financial Performance – P&L Statement

Particulars (₹ Mn)	Q3FY26	Q3FY25	YoY	Q2FY26	QoQ	9MFY26	9MFY25	YoY
<b>Revenue from Operations</b>	3,932	2,750	43.0%	3,062	28.4%	9,066	6,984	29.8%
COGS	1,692	1,478		1,355		4,015	3,897	
<b>Gross Profit</b>	2,240	1,272	76.1%	1,707	31.2%	5,051	3,087	63.6%
Gross Margin	57.0%	46.2%		55.8%		55.7%	44.2%	
Employee benefits expenses	299	217		294		843	604	
Other expenses	435	368		461		1,239	1,012	
<b>Total Expenses</b>	2,425	2,063	17.5%	2,109	15.0%	6,097	5,513	10.6%
<b>EBITDA</b>	1,507	687	119.4%	953	58.1%	2,969	1,471	101.8%
EBITDA Margin	38.3%	25.0%		31.1%		32.7%	21.1%	
Depreciation and amortization	98	63		84		264	193	
<b>PBIT</b>	1,408	623	125.9%	869	62.0%	2,705	1,278	111.7%
Finance costs	9	7		6		21	56	
Other Income	47	17		98		305	112	
<b>PBT</b>	1,447	633	128.4%	962		2,989	1,333	124.2%
Tax Expense	385	179		243		768	356	
<b>PAT</b>	1,062	454	133.7%	719	47.8%	2,221	977	127.3%
PAT Margin	27.0%	16.5%		23.5%		24.5%	14.0%	

# Financial Performance over the years – Key Metrics

## Revenue from Operations- Growth Trends

FY20-25 CAGR:


**29.8%**

**83.2%**

**33.3%**

(₹ Mn.)

■ FY20 ■ FY21 ■ FY22 ■ FY23 ■ FY24 ■ FY25 ■ 9MFY26



## EBITDA and EBITDA Margins

■ EBITDA (₹ Mn)

■ EBITDA Margin (%)

(₹ Mn. & %)

17.1%

32.7%

23.5%

20.2%

19.9%

17.9%

23.0%

410

2,969

802

2,321

1,052

1,227

1,285

1,285


FY20

9MFY26

## Revenue – by Business Verticals

(%)

■ Pharma Intermediates ■ Specialty Chemicals




## Returns Profile#

(%)

■ ROCE

■ ROE




## PAT and PAT Margins

(₹ Mn & %)

■ PAT (₹ Mn)

■ PAT Margin (%)



#ROE and ROCE adjusted for Cash & Cash Equivalents, Exceptional Items, CWIP

Note: PAT for FY24 is adjusted for Exceptional Items

# Financial Performance over the years - Profit and Loss


Particulars (₹ Mn.)	FY21	FY22	FY23	FY24	FY25	9MFY26
Revenue from Operations	3,406	5,201	6,167	7,175	10,069	9,066
Other Income	14	28	43	75	169	305
<b>Total Income</b>	<b>3,420</b>	<b>5,229</b>	<b>6,210</b>	<b>7,250</b>	<b>10,238</b>	<b>9,371</b>
Cost of materials consumed	1,749	2,823	3,459	4,402	5,698	4,113
Changes in inventories of finished goods, traded goods and work-in-progress	48	(95)	(150)	(285)	(176)	(98)
Employee benefits expenses	210	414	488	631	837	843
Finance cost	56	64	24	59	62	21
Depreciation and amortisation expenses	42	101	123	161	266	264
Other expenses	598	1,008	1,144	1,142	1,390	1,239
<b>Total Expense</b>	<b>2,703</b>	<b>4,315</b>	<b>5,088</b>	<b>6,110</b>	<b>8,077</b>	<b>6,382</b>
<b>Profit before tax and exceptional items</b>	<b>717</b>	<b>914</b>	<b>1,122</b>	<b>1,140</b>	<b>2,162</b>	<b>2,989</b>
Exceptional profit / (loss)	-	-	-	(321)	-	-
Tax expense	177	195	289	332	557	768
<b>Profit for the year</b>	<b>540</b>	<b>719</b>	<b>833</b>	<b>487</b>	<b>1,604</b>	<b>2,221</b>

# Financial Performance over the years - Balance Sheet

Assets (₹ Mn.)	FY21	FY22	FY23	FY24	FY25	H1 FY26	Equity and Liabilities (₹ Mn.)	FY21	FY22	FY23	FY24	FY25	H1 FY26
Property, plant and equipment	1,422	1,584	1,844	3,229	4,629	5,698	Shareholder's equity	1,669	5,223	5,939	6,828	13,201	14,391
Right of use assets	184	194	374	372	424	498	Financial Liabilities	726	6	6	1,136	48	81
Capital work-in-progress	2	30	255	1,254	1,303	1,519	Provisions	44	4	7	13	25	33
Goodwill	-	-	203	568	568	733	Deferred tax liabilities (net)	33	63	88	130	196	259
Other intangible assets	257	267	211	103	83	73	<b>Total non-current liabilities</b>	<b>803</b>	<b>73</b>	<b>101</b>	<b>1,280</b>	<b>269</b>	<b>374</b>
Investments	14	17	17	2	2	2	Borrowings	640	3	30	1,030	82	2
Other financial assets	27	108	65	26	49	69	Trade payables	848	1,184	1,420	1,346	1,560	1,492
Current tax assets (net)	-	49	32	25	2	-	Other current liabilities	151	46	64	344	135	344
Other non-current assets	64	97	129	447	517	465	Provisions	10	60	114	132	245	321
<b>Total non-current assets</b>	<b>1,970</b>	<b>2,346</b>	<b>3,130</b>	<b>6,026</b>	<b>7,577</b>	<b>9,058</b>	Current tax liabilities (net)	11	-	-	-	-	33
Inventories	604	1,122	1,192	1,567	1,799	1,910	<b>Total current liabilities</b>	<b>1,660</b>	<b>1,293</b>	<b>1,628</b>	<b>2,852</b>	<b>2,022</b>	<b>2,192</b>
Trade receivables	1,207	1,637	2,303	2,064	2,905	2,915	<b>Total liabilities</b>	<b>2,463</b>	<b>1,366</b>	<b>1,730</b>	<b>4,131</b>	<b>2,292</b>	<b>2,566</b>
Cash and cash equivalents	27	103	305	297	1,852	1,725	<b>Total equity and liabilities</b>	<b>4,133</b>	<b>6,589</b>	<b>7,669</b>	<b>10,959</b>	<b>15,493</b>	<b>16,956</b>
Other bank balances	-	893	281	236	637	682							
Loans	3	6	13	16	22	21							
Other current assets	321	481	445	753	701	646							
<b>Total current assets</b>	<b>2,162</b>	<b>4,291</b>	<b>4,571</b>	<b>4,958</b>	<b>7,918</b>	<b>7,899</b>							
<b>Total assets</b>	<b>4,133</b>	<b>6,589</b>	<b>7,669</b>	<b>10,959</b>	<b>15,493</b>	<b>16,956</b>							

# Shareholder Information

Shareholding as on 31<sup>st</sup> December 2025



Source: BSE

Earnings Presentation | January 2026

Share Information as on 31<sup>st</sup> December 2025

NSE Ticker	<b>ACUTAAS</b>
BSE Ticker	<b>543349</b>
Market Cap (₹ Cr.)	<b>13,958</b>
Shares Outstanding	<b>8,18,71,122</b>
3M ADTV (Shares)	<b>3,50,109</b>
3M ADTV (₹ Cr.)	<b>59.2</b>
Industry	<b>Specialty Chemicals</b>


Source: NSE



The Presentation is to provide the general background information about the Company's activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. The Company makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information contained herein.

This presentation may include certain "forward looking statements". These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others, general economic and business conditions in India and abroad, ability to successfully implement our strategy, our research & development efforts, our growth & expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global pharmaceutical and chemical industries, increasing competition, changes in political conditions in India or any other country and changes in the foreign exchange control regulations in India. Neither the company, nor its Directors and any of the affiliates or employee have any obligation to update or otherwise revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein.

No part of this presentation may be reproduced, quoted or circulated without prior written approval from Acutaas Chemicals Ltd.



## Contact Us

For more information please contact:

---

### **Acutaas Chemicals Limited**

#### **Ekta Srivastava**

Company Secretary & Compliance Officer  
[cs@acutaas.com](mailto:cs@acutaas.com)

#### **Rahul Thakur**

Senior Manager – Investor Relations  
[Rahul.thakur@acutaas.com](mailto:Rahul.thakur@acutaas.com)